Clinical trials: Brain Tumor
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03642067
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
This is a single-arm, phase II trial of SOM230 in patients with documented recurrent or progressive intracranial meningioma who have failed conventional therapy and are not candidates for complete surgical resection of their…
- Trial name
- NCT00813592
- Testing
- SOM230B
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Utah
Radionecrosis, Brain Metastases
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard…
- Trial name
- NCT02490878
- Testing
- bevacizumab, corticosteroids
- Where
- 341 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Brain Metastases
A Proof-of-principle Study of HBO-SRS for Brain Metastases
Patients with brain metastases who are candidates for treatment with stereotactic radiosurgery (SRS) are potential study participants.
- Trial name
- NCT01850563
- Testing
- Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Hemostasis, Meningioma Surgery
Phase IV Bioseal Study in Brain Tumor Surgery
The objective of this study is to observe the clinical utility and performance of Bioseal when used as an adjunct to hemostasis versus Standard of Care (SoC) in elective meningioma surgery.
- Trial name
- NCT02034799
- Testing
- Bioseal Fibrin Sealant, Standard of Care (SoC)
- Where
- 7 sites in China
- Volunteers
- 256 people
- Sponsor
- Ethicon, Inc.
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00983359
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
This research study is studying a drug called GDC-0084 as a possible treatment for HER2-Positive Breast Cancer. The drugs involved in this study are: GDC-0084 Trastuzumab (Herceptin®)
- Trial name
- NCT03765983
- Testing
- Trastuzumab, GDC-0084
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Hypothyroidism, Brain Tumor
Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors
Primary Objectives: 1. Assess whether combined treatment with Levothyroxine and Liothyronine improves learning and memory. 2. Explore the relationship between T3 treatment and other domains of cognitive function, quality of life…
- Trial name
- NCT00488644
- Testing
- Levothyroxine, Liothyronine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Neoplasms, Adult, Malignant
Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis
SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses.
- Trial name
- SRS (NCT02645487)
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Glioma, Pilocytic Astrocytoma
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
By employing a combination of advanced MRI techniques and correlative serum biomarkers of blood brain barrier (BBB) disruption, the investigators plan to develop a powerful, first of its kind clinical algorithm in pediatrics…
- Conditions
- Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT02372409
- Testing
- MRI-guided laser ablation, Doxorubicin, Etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Brain Metastases From Non-small Cell Lung Cancer
Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
The primary objective of this study is to evaluate the efficacy and safety of veliparib and whole brain radiation therapy in adults with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT01657799
- Testing
- Veliparib, Whole brain radiation therapy
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Benign Brain Tumor, Malignant Brain Tumor
Evaluation of cCeLL-Ex Vivo Confocal Microscopy for Real-time Brain Tumor Diagnosis
Intra-operative evaluation of residual brain tumor currently relies on frozen-section histopathology, which typically requires 20-30 minutes for tissue processing and interpretation, prolonging operative time and increasing…
- Trial name
- cCeLLExvivo (NCT06098248)
- Testing
- cCeLL - Ex vivo
- Where
- 4 sites in Canada, South Korea
- Volunteers
- 285 people
- Sponsor
- VPIX Medical
Chronic Disease, Neoplasm Metastasis
Facilitating Communication Study
This study is a randomized clinical trial of an intervention to improve outcomes for patients and their family by using ICU nurse facilitators to support, model, and teach communication strategies that enable patients and their…
- Conditions
- Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive
- Trial name
- FCS2 (NCT03721952)
- Testing
- Facilitator-Based Intervention
- Where
- 3 sites in United States
- Volunteers
- 977 people
- Sponsor
- University of Washington
High-Grade Gliomas
Bevacizumab and Irinotecan to Treat Brain Tumors
Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. It has shown activity against human brain tumors in laboratory tests and human clinical trials.
- Trial name
- NCT00393094
- Testing
- Bevacizumab, Irinotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Cushing's Disease
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly…
- Trial name
- NCT00612066
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well vorinostat works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00238303
- Testing
- vorinostat, conventional surgery
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor
Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma
The main purpose of this part of the study is to determine the Central Nervous System bioavailability of sulfasalazine.
- Trial name
- NCT01577966
- Testing
- Sulfasalazine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Alabama at Birmingham
Cerebral Cavernous Malformation
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic…
- Trial name
- SYCAMORE (NCT05085561)
- Testing
- REC-994
- Where
- 15 sites in United States
- Volunteers
- 62 people
- Sponsor
- Recursion Pharmaceuticals Inc.